## Answer
(model generated chain of thought explanation)

Given the scenario, we need to identify the anticoagulant that was most likely administered to the patient.

Firstly, let's consider the effects of each option on hematochezia (hemorrhage in the rectum):

- A. Warfarin: This is an oral anticoagulant that works by inhibiting vitamin K-dependent clotting factors. It can cause gastrointestinal bleeding, including hematochezia.
- B. Enoxaparin: This is a low molecular weight heparin (LMWH) that also works by inhibiting vitamin K-dependent clotting factors. Like warfarin, it can cause gastrointestinal bleeding and is known to be associated with significant hematochezia in some patients.
- C. Heparin: This is another type of anticoagulant that works by activating antithrombin III, which then inhibits thrombin and other clotting factors. It's less likely to cause significant gastrointestinal bleeding compared to warfarin or LMWHs like enoxaparin.
- D. Dabigatran: This is a direct oral anticoagulant (DOAC) that works by inhibiting thrombin directly. While it can cause gastrointestinal bleeding, it's generally considered safer than the other options listed.

Given that the patient developed significant hematochezia after being treated with an anticoagulant and that both warfarin and enoxaparin are known to cause this side effect, we can infer that either of these medications was likely administered. However, considering the patient's history of deep venous thrombosis (DVT) and the fact that he developed significant hematochezia after being treated with an anticoagulant, it is more likely that the patient received enoxaparin.

The effects of protamine administration are also consistent with warfarin use. Protamine sulfate is used to reverse the anticoagulant effects of heparin, and its administration can be associated with a rapid reversal of anticoagulation, which aligns with the patient's significant hematochezia after receiving enoxaparin.

Therefore, based on the information provided and the typical side effect profiles of these medications, it is most likely that the anticoagulant administered to this patient was warfarin.